Oral oncology · 2025
Prevalence, risk Factors, and quality of life in patients with head and neck lymphedema following treatment for head and neck Cancer: The HeNLy-1 study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thiagarajan Shivakumar, Rukmangathan T, Sharma Drub, Kakade Aniket, Balaji Arun, Rebeka Marri, Noronha Vanita, Prabhash Kumar, Ghosh-Laskar Sarbani, Pantvaidya Gouri
Аннотация
BACKGROUND: Patients treated for head & neck cancer (HNC) are at risk of developing head and neck lymphedema (HNL) that may impact their functions and quality of life (QoL). This study aimed to assess the prevalence of HNL, its risk factors, and evaluate its impact on QoL.
METHODS: In this observational (cross-sectional) study, we included adult HNC patients who had completed definitive treatment at least 6 months prior and who had received some part of their treatment at our institute. The external lymphedema was rated using the MD Anderson Cancer Centre (MDACC) HNL rating system, and internal lymphedema using Patterson's scale. Health-related QoL was assessed using the University of Washington quality of life questionnaire.
RESULTS: A total of 421 were enrolled, with a median duration post-treatment of 19 months. HNL was present in 190 patients (45.1 %), either internal or external lymphedema or both. Most of them had stage 1a HNL. Factors that predisposed to the development of HNL were age (>47 years) [p = 0.002, 1.993(1.279-2.935)], tobacco use [p = 0.025, 1.864(1.081-3.214)], and the type of treatment received, especially those who received definitive chemoradiotherapy [p < 0.001,9.750(4.063-23.395)]. Patients with HNL, especially internal lymphedema, reported significantly more QoL impairments, particularly related to swallowing, chewing, xerostomia, taste and mood.
CONCLUSION: HNL was present in 45.1% of the patients in our cohort, predominantly stage 1a. Age, tobacco use, and treatment received predisposed the patient to develop HNL. Patients with internal lymphedema particularly had swallowing-related QoL issues.
METHODS: In this observational (cross-sectional) study, we included adult HNC patients who had completed definitive treatment at least 6 months prior and who had received some part of their treatment at our institute. The external lymphedema was rated using the MD Anderson Cancer Centre (MDACC) HNL rating system, and internal lymphedema using Patterson's scale. Health-related QoL was assessed using the University of Washington quality of life questionnaire.
RESULTS: A total of 421 were enrolled, with a median duration post-treatment of 19 months. HNL was present in 190 patients (45.1 %), either internal or external lymphedema or both. Most of them had stage 1a HNL. Factors that predisposed to the development of HNL were age (>47 years) [p = 0.002, 1.993(1.279-2.935)], tobacco use [p = 0.025, 1.864(1.081-3.214)], and the type of treatment received, especially those who received definitive chemoradiotherapy [p < 0.001,9.750(4.063-23.395)]. Patients with HNL, especially internal lymphedema, reported significantly more QoL impairments, particularly related to swallowing, chewing, xerostomia, taste and mood.
CONCLUSION: HNL was present in 45.1% of the patients in our cohort, predominantly stage 1a. Age, tobacco use, and treatment received predisposed the patient to develop HNL. Patients with internal lymphedema particularly had swallowing-related QoL issues.